Table of Content

1 T-Cell & NK-Cell Engaging Bispecific Antibodies Market Overview
1.1 Product Overview and Scope of T-Cell & NK-Cell Engaging Bispecific Antibodies
1.2 T-Cell & NK-Cell Engaging Bispecific Antibodies Segment by Type
1.2.1 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Growth Rate Comparison by Type (2021-2027)
1.2.2 Recombinant Monoclonal Antibodies
1.2.3 In-House Bispecific Antibodies
1.3 T-Cell & NK-Cell Engaging Bispecific Antibodies Segment by Application
1.3.1 T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Comparison by Application: (2021-2027)
1.3.2 Immunotherapy of Cancer
1.3.3 Clinical Experiment
1.4 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size Estimates and Forecasts
1.4.1 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue 2016-2027
1.4.2 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales 2016-2027
1.4.3 T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Region: 2016 Versus 2021 Versus 2027

2 T-Cell & NK-Cell Engaging Bispecific Antibodies Market Competition by Manufacturers
2.1 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Market Share by Manufacturers (2016-2021)
2.2 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Market Share by Manufacturers (2016-2021)
2.3 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Average Price by Manufacturers (2016-2021)
2.4 Manufacturers T-Cell & NK-Cell Engaging Bispecific Antibodies Manufacturing Sites, Area Served, Product Type
2.5 T-Cell & NK-Cell Engaging Bispecific Antibodies Market Competitive Situation and Trends
2.5.1 T-Cell & NK-Cell Engaging Bispecific Antibodies Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest T-Cell & NK-Cell Engaging Bispecific Antibodies Players Market Share by Revenue
2.5.3 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans

3 T-Cell & NK-Cell Engaging Bispecific Antibodies Retrospective Market Scenario by Region
3.1 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Retrospective Market Scenario in Revenue by Region: 2016-2021
3.2 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Retrospective Market Scenario in Sales by Region: 2016-2021
3.3 North America T-Cell & NK-Cell Engaging Bispecific Antibodies Market Facts & Figures by Country
3.3.1 North America T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Country
3.3.2 North America T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue by Country
3.3.3 U.S.
3.3.4 Canada
3.4 Europe T-Cell & NK-Cell Engaging Bispecific Antibodies Market Facts & Figures by Country
3.4.1 Europe T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Country
3.4.2 Europe T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific T-Cell & NK-Cell Engaging Bispecific Antibodies Market Facts & Figures by Region
3.5.1 Asia Pacific T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Region
3.5.2 Asia Pacific T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.5.12 Philippines
3.5.13 Vietnam
3.6 Latin America T-Cell & NK-Cell Engaging Bispecific Antibodies Market Facts & Figures by Country
3.6.1 Latin America T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Country
3.6.2 Latin America T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.7 Middle East and Africa T-Cell & NK-Cell Engaging Bispecific Antibodies Market Facts & Figures by Country
3.7.1 Middle East and Africa T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Country
3.7.2 Middle East and Africa T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 UAE
4 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Historic Market Analysis by Type
4.1 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Market Share by Type (2016-2021)
4.2 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Market Share by Type (2016-2021)
4.3 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Price by Type (2016-2021)

5 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Historic Market Analysis by Application
5.1 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Market Share by Application (2016-2021)
5.2 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Market Share by Application (2016-2021)
5.3 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Price by Application (2016-2021)

6 Key Companies Profiled
6.1 AbbVie
6.1.1 AbbVie Corporation Information
6.1.2 AbbVie Description and Business Overview
6.1.3 AbbVie T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Revenue and Gross Margin (2016-2021)
6.1.4 AbbVie Product Portfolio
6.1.5 AbbVie Recent Developments/Updates
6.2 Astellas Pharma
6.2.1 Astellas Pharma Corporation Information
6.2.2 Astellas Pharma Description and Business Overview
6.2.3 Astellas Pharma T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Revenue and Gross Margin (2016-2021)
6.2.4 Astellas Pharma Product Portfolio
6.2.5 Astellas Pharma Recent Developments/Updates
6.3 GEMoaB Monoclonals
6.3.1 GEMoaB Monoclonals Corporation Information
6.3.2 GEMoaB Monoclonals Description and Business Overview
6.3.3 GEMoaB Monoclonals T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Revenue and Gross Margin (2016-2021)
6.3.4 GEMoaB Monoclonals Product Portfolio
6.3.5 GEMoaB Monoclonals Recent Developments/Updates
6.4 Immunocore
6.4.1 Immunocore Corporation Information
6.4.2 Immunocore Description and Business Overview
6.4.3 Immunocore T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Revenue and Gross Margin (2016-2021)
6.4.4 Immunocore Product Portfolio
6.4.5 Immunocore Recent Developments/Updates
6.5 Molecular Partners
6.5.1 Molecular Partners Corporation Information
6.5.2 Molecular Partners Description and Business Overview
6.5.3 Molecular Partners T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Revenue and Gross Margin (2016-2021)
6.5.4 Molecular Partners Product Portfolio
6.5.5 Molecular Partners Recent Developments/Updates
6.6 Roche
6.6.1 Roche Corporation Information
6.6.2 Roche Description and Business Overview
6.6.3 Roche T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Revenue and Gross Margin (2016-2021)
6.6.4 Roche Product Portfolio
6.6.5 Roche Recent Developments/Updates
6.7 AstraZeneca
6.6.1 AstraZeneca Corporation Information
6.6.2 AstraZeneca Description and Business Overview
6.6.3 AstraZeneca T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Revenue and Gross Margin (2016-2021)
6.4.4 AstraZeneca Product Portfolio
6.7.5 AstraZeneca Recent Developments/Updates
6.8 Merck & Co.
6.8.1 Merck & Co. Corporation Information
6.8.2 Merck & Co. Description and Business Overview
6.8.3 Merck & Co. T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Revenue and Gross Margin (2016-2021)
6.8.4 Merck & Co. Product Portfolio
6.8.5 Merck & Co. Recent Developments/Updates
6.9 Pfizer
6.9.1 Pfizer Corporation Information
6.9.2 Pfizer Description and Business Overview
6.9.3 Pfizer T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Revenue and Gross Margin (2016-2021)
6.9.4 Pfizer Product Portfolio
6.9.5 Pfizer Recent Developments/Updates
6.10 Eli Lilly
6.10.1 Eli Lilly Corporation Information
6.10.2 Eli Lilly Description and Business Overview
6.10.3 Eli Lilly T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Revenue and Gross Margin (2016-2021)
6.10.4 Eli Lilly Product Portfolio
6.10.5 Eli Lilly Recent Developments/Updates
6.11 IGM Biosciences
6.11.1 IGM Biosciences Corporation Information
6.11.2 IGM Biosciences T-Cell & NK-Cell Engaging Bispecific Antibodies Description and Business Overview
6.11.3 IGM Biosciences T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Revenue and Gross Margin (2016-2021)
6.11.4 IGM Biosciences Product Portfolio
6.11.5 IGM Biosciences Recent Developments/Updates
6.12 Novartis
6.12.1 Novartis Corporation Information
6.12.2 Novartis T-Cell & NK-Cell Engaging Bispecific Antibodies Description and Business Overview
6.12.3 Novartis T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Revenue and Gross Margin (2016-2021)
6.12.4 Novartis Product Portfolio
6.12.5 Novartis Recent Developments/Updates
6.13 BenHealth Biopharmaceuticals
6.13.1 BenHealth Biopharmaceuticals Corporation Information
6.13.2 BenHealth Biopharmaceuticals T-Cell & NK-Cell Engaging Bispecific Antibodies Description and Business Overview
6.13.3 BenHealth Biopharmaceuticals T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Revenue and Gross Margin (2016-2021)
6.13.4 BenHealth Biopharmaceuticals Product Portfolio
6.13.5 BenHealth Biopharmaceuticals Recent Developments/Updates
6.14 CytomX Therapeutics
6.14.1 CytomX Therapeutics Corporation Information
6.14.2 CytomX Therapeutics T-Cell & NK-Cell Engaging Bispecific Antibodies Description and Business Overview
6.14.3 CytomX Therapeutics T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Revenue and Gross Margin (2016-2021)
6.14.4 CytomX Therapeutics Product Portfolio
6.14.5 CytomX Therapeutics Recent Developments/Updates
6.15 Janssen
6.15.1 Janssen Corporation Information
6.15.2 Janssen T-Cell & NK-Cell Engaging Bispecific Antibodies Description and Business Overview
6.15.3 Janssen T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Revenue and Gross Margin (2016-2021)
6.15.4 Janssen Product Portfolio
6.15.5 Janssen Recent Developments/Updates
6.16 Lava Therapeutics
6.16.1 Lava Therapeutics Corporation Information
6.16.2 Lava Therapeutics T-Cell & NK-Cell Engaging Bispecific Antibodies Description and Business Overview
6.16.3 Lava Therapeutics T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Revenue and Gross Margin (2016-2021)
6.16.4 Lava Therapeutics Product Portfolio
6.16.5 Lava Therapeutics Recent Developments/Updates
6.17 MacroGenics
6.17.1 MacroGenics Corporation Information
6.17.2 MacroGenics T-Cell & NK-Cell Engaging Bispecific Antibodies Description and Business Overview
6.17.3 MacroGenics T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Revenue and Gross Margin (2016-2021)
6.17.4 MacroGenics Product Portfolio
6.17.5 MacroGenics Recent Developments/Updates
6.18 Maverick Therapeutics
6.18.1 Maverick Therapeutics Corporation Information
6.18.2 Maverick Therapeutics T-Cell & NK-Cell Engaging Bispecific Antibodies Description and Business Overview
6.18.3 Maverick Therapeutics T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Revenue and Gross Margin (2016-2021)
6.18.4 Maverick Therapeutics Product Portfolio
6.18.5 Maverick Therapeutics Recent Developments/Updates
6.19 VBL Therapeutics
6.19.1 VBL Therapeutics Corporation Information
6.19.2 VBL Therapeutics T-Cell & NK-Cell Engaging Bispecific Antibodies Description and Business Overview
6.19.3 VBL Therapeutics T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Revenue and Gross Margin (2016-2021)
6.19.4 VBL Therapeutics Product Portfolio
6.19.5 VBL Therapeutics Recent Developments/Updates
6.20 Amgen
6.20.1 Amgen Corporation Information
6.20.2 Amgen T-Cell & NK-Cell Engaging Bispecific Antibodies Description and Business Overview
6.20.3 Amgen T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Revenue and Gross Margin (2016-2021)
6.20.4 Amgen Product Portfolio
6.20.5 Amgen Recent Developments/Updates

7 T-Cell & NK-Cell Engaging Bispecific Antibodies Manufacturing Cost Analysis
7.1 T-Cell & NK-Cell Engaging Bispecific Antibodies Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of T-Cell & NK-Cell Engaging Bispecific Antibodies
7.4 T-Cell & NK-Cell Engaging Bispecific Antibodies Industrial Chain Analysis

8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 T-Cell & NK-Cell Engaging Bispecific Antibodies Distributors List
8.3 T-Cell & NK-Cell Engaging Bispecific Antibodies Customers

9 T-Cell & NK-Cell Engaging Bispecific Antibodies Market Dynamics
9.1 T-Cell & NK-Cell Engaging Bispecific Antibodies Industry Trends
9.2 T-Cell & NK-Cell Engaging Bispecific Antibodies Growth Drivers
9.3 T-Cell & NK-Cell Engaging Bispecific Antibodies Market Challenges
9.4 T-Cell & NK-Cell Engaging Bispecific Antibodies Market Restraints

10 Global Market Forecast
10.1 T-Cell & NK-Cell Engaging Bispecific Antibodies Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of T-Cell & NK-Cell Engaging Bispecific Antibodies by Type (2022-2027)
10.1.2 Global Forecasted Revenue of T-Cell & NK-Cell Engaging Bispecific Antibodies by Type (2022-2027)
10.2 T-Cell & NK-Cell Engaging Bispecific Antibodies Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of T-Cell & NK-Cell Engaging Bispecific Antibodies by Application (2022-2027)
10.2.2 Global Forecasted Revenue of T-Cell & NK-Cell Engaging Bispecific Antibodies by Application (2022-2027)
10.3 T-Cell & NK-Cell Engaging Bispecific Antibodies Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of T-Cell & NK-Cell Engaging Bispecific Antibodies by Region (2022-2027)
10.3.2 Global Forecasted Revenue of T-Cell & NK-Cell Engaging Bispecific Antibodies by Region (2022-2027)

11 Research Finding and Conclusion

12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer

List of Figure

List of Tables
Table 1. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales (ml) Growth Rate Comparison by Type (2021-2027)
Table 2. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales (ml) Comparison by Application (2021-2027)
Table 3. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Region (US$ Million) (2016 VS 2021 VS 2027)
Table 4. Key Manufacturers T-Cell & NK-Cell Engaging Bispecific Antibodies Covered in This Study
Table 5. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales (ml) of Key Manufacturers (2016-2021)
Table 6. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Share by Manufacturers (2016-2021)
Table 7. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue (US$ Million) by Manufacturers (2016-2021)
Table 8. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Share by Manufacturers (2016-2021)
Table 9. Global Market T-Cell & NK-Cell Engaging Bispecific Antibodies Average Price (US$/ml) of Key Manufacturers (2016-2021)
Table 10. Manufacturers T-Cell & NK-Cell Engaging Bispecific Antibodies Manufacturing Sites and Area Served
Table 11. Manufacturers T-Cell & NK-Cell Engaging Bispecific Antibodies Product Type
Table 12. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 13. Global T-Cell & NK-Cell Engaging Bispecific Antibodies by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in T-Cell & NK-Cell Engaging Bispecific Antibodies as of 2020)
Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 15. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Region (2016-2021) & (ml)
Table 16. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Market Share by Region (2016-2021)
Table 17. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue by Region (2016-2021) & (US$ Million)
Table 18. North America T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Country (2016-2021) & (ml)
Table 19. North America T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Market Share by Country (2016-2021)
Table 20. North America T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue by Country (2016-2021) & (US$ Million)
Table 21. North America T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Market Share by Country (2016-2021)
Table 22. Europe T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Country (2016-2021) & (ml)
Table 23. Europe T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Market Share by Country (2016-2021)
Table 24. Europe T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue by Country (2016-2021) & (US$ Million)
Table 25. Europe T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Market Share by Country (2016-2021)
Table 26. Asia Pacific T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Region (2016-2021) & (ml)
Table 27. Asia Pacific T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Market Share by Region (2016-2021)
Table 28. Asia Pacific T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue by Region (2016-2021) & (US$ Million)
Table 29. Asia Pacific T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Market Share by Region (2016-2021)
Table 30. Latin America T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Country (2016-2021) & (ml)
Table 31. Latin America T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Market Share by Country (2016-2021)
Table 32. Latin America T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue by Country (2016-2021) & (US$ Million)
Table 33. Latin America T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Market Share by Country (2016-2021)
Table 34. Middle East and Africa T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Country (2016-2021) & (ml)
Table 35. Middle East and Africa T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Market Share by Country (2016-2021)
Table 36. Middle East and Africa T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue by Country (2016-2021) & (US$ Million)
Table 37. Middle East and Africa T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Market Share by Country (2016-2021)
Table 38. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales (ml) by Type (2016-2021)
Table 39. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Market Share by Type (2016-2021)
Table 40. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue (Million US$) by Type (2016-2021)
Table 41. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Share by Type (2016-2021)
Table 42. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Price (US$/ml) by Type (2016-2021)
Table 43. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales (ml) by Application (2016-2021)
Table 44. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Market Share by Application (2016-2021)
Table 45. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue (Million US$) by Application (2016-2021)
Table 46. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Share by Application (2016-2021)
Table 47. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Price (US$/ml) by Application (2016-2021)
Table 48. AbbVie Corporation Information
Table 49. AbbVie Description and Business Overview
Table 50. AbbVie T-Cell & NK-Cell Engaging Bispecific Antibodies Sales (ml), Revenue (Million US$), Price (US$/ml) and Gross Margin (2016-2021)
Table 51. AbbVie T-Cell & NK-Cell Engaging Bispecific Antibodies Product
Table 52. AbbVie Recent Developments/Updates
Table 53. Astellas Pharma Corporation Information
Table 54. Astellas Pharma Description and Business Overview
Table 55. Astellas Pharma T-Cell & NK-Cell Engaging Bispecific Antibodies Sales (ml), Revenue (Million US$), Price (US$/ml) and Gross Margin (2016-2021)
Table 56. Astellas Pharma T-Cell & NK-Cell Engaging Bispecific Antibodies Product
Table 57. Astellas Pharma Recent Developments/Updates
Table 58. GEMoaB Monoclonals Corporation Information
Table 59. GEMoaB Monoclonals Description and Business Overview
Table 60. GEMoaB Monoclonals T-Cell & NK-Cell Engaging Bispecific Antibodies Sales (ml), Revenue (Million US$), Price (US$/ml) and Gross Margin (2016-2021)
Table 61. GEMoaB Monoclonals T-Cell & NK-Cell Engaging Bispecific Antibodies Product
Table 62. GEMoaB Monoclonals Recent Developments/Updates
Table 63. Immunocore Corporation Information
Table 64. Immunocore Description and Business Overview
Table 65. Immunocore T-Cell & NK-Cell Engaging Bispecific Antibodies Sales (ml), Revenue (Million US$), Price (US$/ml) and Gross Margin (2016-2021)
Table 66. Immunocore T-Cell & NK-Cell Engaging Bispecific Antibodies Product
Table 67. Immunocore Recent Developments/Updates
Table 68. Molecular Partners Corporation Information
Table 69. Molecular Partners Description and Business Overview
Table 70. Molecular Partners T-Cell & NK-Cell Engaging Bispecific Antibodies Sales (ml), Revenue (Million US$), Price (US$/ml) and Gross Margin (2016-2021)
Table 71. Molecular Partners T-Cell & NK-Cell Engaging Bispecific Antibodies Product
Table 72. Molecular Partners Recent Developments/Updates
Table 73. Roche Corporation Information
Table 74. Roche Description and Business Overview
Table 75. Roche T-Cell & NK-Cell Engaging Bispecific Antibodies Sales (ml), Revenue (Million US$), Price (US$/ml) and Gross Margin (2016-2021)
Table 76. Roche T-Cell & NK-Cell Engaging Bispecific Antibodies Product
Table 77. Roche Recent Developments/Updates
Table 78. AstraZeneca Corporation Information
Table 79. AstraZeneca Description and Business Overview
Table 80. AstraZeneca T-Cell & NK-Cell Engaging Bispecific Antibodies Sales (ml), Revenue (Million US$), Price (US$/ml) and Gross Margin (2016-2021)
Table 81. AstraZeneca T-Cell & NK-Cell Engaging Bispecific Antibodies Product
Table 82. AstraZeneca Recent Developments/Updates
Table 83. Merck & Co. Corporation Information
Table 84. Merck & Co. Description and Business Overview
Table 85. Merck & Co. T-Cell & NK-Cell Engaging Bispecific Antibodies Sales (ml), Revenue (Million US$), Price (US$/ml) and Gross Margin (2016-2021)
Table 86. Merck & Co. T-Cell & NK-Cell Engaging Bispecific Antibodies Product
Table 87. Merck & Co. Recent Developments/Updates
Table 88. Pfizer Corporation Information
Table 89. Pfizer Description and Business Overview
Table 90. Pfizer T-Cell & NK-Cell Engaging Bispecific Antibodies Sales (ml), Revenue (Million US$), Price (US$/ml) and Gross Margin (2016-2021)
Table 91. Pfizer T-Cell & NK-Cell Engaging Bispecific Antibodies Product
Table 92. Pfizer Recent Developments/Updates
Table 93. Eli Lilly Corporation Information
Table 94. Eli Lilly Description and Business Overview
Table 95. Eli Lilly T-Cell & NK-Cell Engaging Bispecific Antibodies Sales (ml), Revenue (Million US$), Price (US$/ml) and Gross Margin (2016-2021)
Table 96. Eli Lilly T-Cell & NK-Cell Engaging Bispecific Antibodies Product
Table 97. Eli Lilly Recent Developments/Updates
Table 98. IGM Biosciences Corporation Information
Table 99. IGM Biosciences Description and Business Overview
Table 100. IGM Biosciences T-Cell & NK-Cell Engaging Bispecific Antibodies Sales (ml), Revenue (Million US$), Price (US$/ml) and Gross Margin (2016-2021)
Table 101. IGM Biosciences T-Cell & NK-Cell Engaging Bispecific Antibodies Product
Table 102. IGM Biosciences Recent Developments/Updates
Table 103. Novartis Corporation Information
Table 104. Novartis Description and Business Overview
Table 105. Novartis T-Cell & NK-Cell Engaging Bispecific Antibodies Sales (ml), Revenue (Million US$), Price (US$/ml) and Gross Margin (2016-2021)
Table 106. Novartis T-Cell & NK-Cell Engaging Bispecific Antibodies Product
Table 107. Novartis Recent Developments/Updates
Table 108. BenHealth Biopharmaceuticals Corporation Information
Table 109. BenHealth Biopharmaceuticals Description and Business Overview
Table 110. BenHealth Biopharmaceuticals T-Cell & NK-Cell Engaging Bispecific Antibodies Sales (ml), Revenue (Million US$), Price (US$/ml) and Gross Margin (2016-2021)
Table 111. BenHealth Biopharmaceuticals T-Cell & NK-Cell Engaging Bispecific Antibodies Product
Table 112. BenHealth Biopharmaceuticals Recent Developments/Updates
Table 113. CytomX Therapeutics Corporation Information
Table 114. CytomX Therapeutics Description and Business Overview
Table 115. CytomX Therapeutics T-Cell & NK-Cell Engaging Bispecific Antibodies Sales (ml), Revenue (Million US$), Price (US$/ml) and Gross Margin (2016-2021)
Table 116. CytomX Therapeutics T-Cell & NK-Cell Engaging Bispecific Antibodies Product
Table 117. CytomX Therapeutics Recent Developments/Updates
Table 118. Janssen Corporation Information
Table 119. Janssen Description and Business Overview
Table 120. Janssen T-Cell & NK-Cell Engaging Bispecific Antibodies Sales (ml), Revenue (Million US$), Price (US$/ml) and Gross Margin (2016-2021)
Table 121. Janssen T-Cell & NK-Cell Engaging Bispecific Antibodies Product
Table 122. Janssen Recent Developments/Updates
Table 123. Lava Therapeutics Corporation Information
Table 124. Lava Therapeutics Description and Business Overview
Table 125. Lava Therapeutics T-Cell & NK-Cell Engaging Bispecific Antibodies Sales (ml), Revenue (Million US$), Price (US$/ml) and Gross Margin (2016-2021)
Table 126. Lava Therapeutics T-Cell & NK-Cell Engaging Bispecific Antibodies Product
Table 127. Lava Therapeutics Recent Developments/Updates
Table 128. MacroGenics Corporation Information
Table 129. MacroGenics Description and Business Overview
Table 130. MacroGenics T-Cell & NK-Cell Engaging Bispecific Antibodies Sales (ml), Revenue (Million US$), Price (US$/ml) and Gross Margin (2016-2021)
Table 131. MacroGenics T-Cell & NK-Cell Engaging Bispecific Antibodies Product
Table 132. MacroGenics Recent Developments/Updates
Table 133. Maverick Therapeutics Corporation Information
Table 134. Maverick Therapeutics Description and Business Overview
Table 135. Maverick Therapeutics T-Cell & NK-Cell Engaging Bispecific Antibodies Sales (ml), Revenue (Million US$), Price (US$/ml) and Gross Margin (2016-2021)
Table 136. Maverick Therapeutics T-Cell & NK-Cell Engaging Bispecific Antibodies Product
Table 137. Maverick Therapeutics Recent Developments/Updates
Table 138. VBL Therapeutics Corporation Information
Table 139. VBL Therapeutics Description and Business Overview
Table 140. VBL Therapeutics T-Cell & NK-Cell Engaging Bispecific Antibodies Sales (ml), Revenue (Million US$), Price (US$/ml) and Gross Margin (2016-2021)
Table 141. VBL Therapeutics T-Cell & NK-Cell Engaging Bispecific Antibodies Product
Table 142. VBL Therapeutics Recent Developments/Updates
Table 143. Amgen Corporation Information
Table 144. Amgen Description and Business Overview
Table 145. Amgen T-Cell & NK-Cell Engaging Bispecific Antibodies Sales (ml), Revenue (Million US$), Price (US$/ml) and Gross Margin (2016-2021)
Table 146. Amgen T-Cell & NK-Cell Engaging Bispecific Antibodies Product
Table 147. Amgen Recent Developments/Updates
Table 148. Production Base and Market Concentration Rate of Raw Material
Table 149. Key Suppliers of Raw Materials
Table 150. T-Cell & NK-Cell Engaging Bispecific Antibodies Distributors List
Table 151. T-Cell & NK-Cell Engaging Bispecific Antibodies Customers List
Table 152. T-Cell & NK-Cell Engaging Bispecific Antibodies Market Trends
Table 153. T-Cell & NK-Cell Engaging Bispecific Antibodies Growth Drivers
Table 154. T-Cell & NK-Cell Engaging Bispecific Antibodies Market Restraints
Table 155. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Forecast by Type (2022-2027) & (ml)
Table 156. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Market Share Forecast by Type (2022-2027)
Table 157. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Forecast by Type (2022-2027) & (US$ Million)
Table 158. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Market Share Forecast by Type (2022-2027)
Table 159. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Forecast by Application (2022-2027) & (ml)
Table 160. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Market Share Forecast by Application (2022-2027)
Table 161. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Forecast by Application (2022-2027) & (US$ Million)
Table 162. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Market Share Forecast by Application (2022-2027)
Table 163. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Forecast by Region (2022-2027) & (ml)
Table 164. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Market Share Forecast by Region (2022-2027)
Table 165. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Forecast by Region (2022-2027) & (US$ Million)
Table 166. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Market Share Forecast by Region (2022-2027)
Table 167. Research Programs/Design for This Report
Table 168. Key Data Information from Secondary Sources
Table 169. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of T-Cell & NK-Cell Engaging Bispecific Antibodies
Figure 2. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market Share by Type in 2020 & 2027
Figure 3. Recombinant Monoclonal Antibodies Product Picture
Figure 4. In-House Bispecific Antibodies Product Picture
Figure 5. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market Share by Application in 2020 & 2027
Figure 6. Immunotherapy of Cancer
Figure 7. Clinical Experiment
Figure 8. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue, (US$ Million), 2016 VS 2021 VS 2027
Figure 9. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size 2016-2027 (US$ Million)
Figure 10. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales 2016-2027 (ml)
Figure 11. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size Market Share by Region: 2016 VS 20210 VS 2027
Figure 12. T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Share by Manufacturers in 2020
Figure 13. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Share by Manufacturers in 2020
Figure 14. The Global 5 and 10 Largest T-Cell & NK-Cell Engaging Bispecific Antibodies Players: Market Share by Revenue in 2020
Figure 15. T-Cell & NK-Cell Engaging Bispecific Antibodies Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2021
Figure 16. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Market Share by Region (2016-2021)
Figure 17. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Market Share by Region in 2020
Figure 18. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Market Share by Region (2016-2021)
Figure 19. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Market Share by Region in 2020
Figure 20. U.S. T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Growth Rate (2016-2021) (US$ Million)
Figure 21. Canada T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Growth Rate (2016-2021) (US$ Million)
Figure 22. Germany T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Growth Rate (2016-2021) (US$ Million)
Figure 23. France T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Growth Rate (2016-2021) (US$ Million)
Figure 24. U.K. T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Growth Rate (2016-2021) (US$ Million)
Figure 25. Italy T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Growth Rate (2016-2021) (US$ Million)
Figure 26. Russia T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Growth Rate (2016-2021) (US$ Million)
Figure 27. China T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Growth Rate (2016-2021) (US$ Million)
Figure 28. Japan T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Growth Rate (2016-2021) (US$ Million)
Figure 29. South Korea T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Growth Rate (2016-2021) (US$ Million)
Figure 30. India T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Growth Rate (2016-2021) (US$ Million)
Figure 31. Australia T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Growth Rate (2016-2021) (US$ Million)
Figure 32. Taiwan T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Growth Rate (2016-2021) (US$ Million)
Figure 33. Indonesia T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Growth Rate (2016-2021) (US$ Million)
Figure 34. Thailand T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Growth Rate (2016-2021) (US$ Million)
Figure 35. Malaysia T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Growth Rate (2016-2021) (US$ Million)
Figure 36. Philippines T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Growth Rate (2016-2021) (US$ Million)
Figure 37. Vietnam T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Growth Rate (2016-2021) (US$ Million)
Figure 38. Mexico T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Growth Rate (2016-2021) (US$ Million)
Figure 39. Brazil T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Growth Rate (2016-2021) (US$ Million)
Figure 40. Argentina T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Growth Rate (2016-2021) (US$ Million)
Figure 41. Turkey T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Growth Rate (2016-2021) (US$ Million)
Figure 42. Saudi Arabia T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Growth Rate (2016-2021) (US$ Million)
Figure 43. UAE T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Growth Rate (2016-2021) (US$ Million)
Figure 44. Sales Market Share of T-Cell & NK-Cell Engaging Bispecific Antibodies by Type (2016-2021)
Figure 45. Sales Market Share of T-Cell & NK-Cell Engaging Bispecific Antibodies by Application (2016-2021)
Figure 46. Sales Market Share of T-Cell & NK-Cell Engaging Bispecific Antibodies by Application in 2020
Figure 47. Revenue Share of T-Cell & NK-Cell Engaging Bispecific Antibodies by Application (2016-2021)
Figure 48. Revenue Share of T-Cell & NK-Cell Engaging Bispecific Antibodies by Application in 2020
Figure 49. Manufacturing Cost Structure of T-Cell & NK-Cell Engaging Bispecific Antibodies
Figure 50. Manufacturing Process Analysis of T-Cell & NK-Cell Engaging Bispecific Antibodies
Figure 51. T-Cell & NK-Cell Engaging Bispecific Antibodies Industrial Chain Analysis
Figure 52. Channels of Distribution
Figure 53. Distributors Profiles
Figure 54. Bottom-up and Top-down Approaches for This Report
Figure 55. Data Triangulation
Figure 56. Key Executives Interviewed